Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/immunology.4.128
Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer’s Disease than Amyloid or Tau
Tyler C. Hammond1,2, Ai-Ling Lin1,3,4,*
- 1Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, US
- 2Department of Neuroscience, University of Kentucky, Lexington, KY, USA
- 3Department of Pharmacology and Nutritional Sciences, University of Kentucky, Lexington, KY, USA
- 4Department of Radiology and Biological Sciences, University of Missouri, Columbia, MO, USA
Corresponding Author
Ai-Ling Lin, ai-ling.lin@health.missouri.edu
Received Date: October 06, 2021
Accepted Date: January 24, 2022
Hammond TC, Lin A-L. Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer’s Disease than Amyloid or Tau. J Cell Immunol. 2022;4(1):15-18.
Copyright: © 2022 Hammond TC, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Do Support Vector Machines Play a Role in Stratifying Patient Population Based on Cancer Biomarkers
Cancer is a worldwide public health issue that affects millions of people every year. In 2018 there were 17 million newly documented cases of cancer globally (8.8 million in men and 8.2 million in women), leading to 9.6 million deaths. Cancer is a vastly heterogeneous disease, with over 100 different types of cancer currently identified in humans; the most common types of cancer are lung, female breast, bowel and prostate, these four types account for more than 40% of all new cancer case
Body Mass Index and Treatment Response in Patients with Cardiac Light-Chain Amyloidosis
Elevated body mass index (BMI) has been associated with an increased risk of cancer and has been shown to have a negative impact on survival in patients with breast, prostate, oral cancer, and leukemia. In plasma cell dyscrasias, obesity has not only been shown to be a risk factor for the development of multiple myeloma, but also has been associated with a higher rate of progression from monoclonal gammopathy of unknown significance (MGUS) to multiple myeloma, and if intervened on, has bee
Salivary Protein Antigens for Breast Cancer Biomarkers
Breast Cancer is the most regularly diagnosed type of cancer in women in the world, making up on its own 25% of all cases, or nearly 2 million new cases in 2018, and 15% of all cancer related deaths, or around 626,700 deaths for that same year.
Is Platelet Desialylation a Novel Biomarker and Therapeutic Target in Immune Thrombocytopenia?
Immune thrombocytopenia is an autoimmune disease predominantly caused by autoantibody mediated platelet and megakaryocyte destruction and or dysfunction, which leads to low platelet counts and risk of bleeding. Currently prognostic biomarkers are underdeveloped and there lacks a gold-standard for therapeutics, which leaves an inexplicable refractory subset of patients which are clinically challenging.
Exercise Benefits on Alzheimer’s Disease
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder [1] and the most common cause of human dementia, accounting for approximately 60%?80% of cases. It is estimated that more than 30 million AD patients, and the number likely to increase to over 100 million by 2050 because of the increase of the elderly population [2].